Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080893 | 1.00 | KDM5A (0.41) | KDM5AKDM4CPHF8DNM1KDM5C | |
| SCHEMBL5119055 | 0.98 | KDM5A (0.39) | KDM5AKDM4CPHF8DNM1KDM5C | |
| SCHEMBL7082103 | 0.85 | CA12 (0.45) | KDM5AKDM4CPHF8 | |
| SCHEMBL7085361 | 0.85 | CA12 (0.45) | KDM5AKDM4CPHF8 | |
| SCHEMBL27582512 | 0.84 | DNM1 (0.38) | KDM5AKDM4CPHF8DNM1 | |
| SCHEMBL27582508 | 0.84 | DNM1 (0.38) | KDM5AKDM4CPHF8DNM1 | |
| SCHEMBL7086990 | 0.83 | CA12 (0.46) | KDM5AKDM4CKDM5CKDM5B | |
| SCHEMBL7080922 | 0.77 | CA12 (0.47) | — | |
| SCHEMBL15135141 | 0.77 | ALDH1A1 (0.36) | — | |
| SCHEMBL10317236 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | KDM5A 2214/4885KDM4C 2629/4885PHF8 2778/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | KDM5A 2416/4885KDM4C 3462/4885PHF8 2924/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | KDM5A 2214/4885KDM4C 2629/4885PHF8 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.